Showing results (251-260 of 394) with videos related to
Sort By:
Pageof 40
Molecular Biology of the Cell|July 28, 2010
A phosphatidic acid binding/nuclear localization motif determines lipin1 function in lipid metabolism and adipogenesisHongmei Ren, Lorenzo Federico, Huiyan Huang, et al.The Journal of Antimicrobial Chemotherapy|November 29, 2007
Microbiological effects of prior vancomycin use in patients with methicillin-resistant Staphylococcus aureus bacteraemiaPamela A Moise, Davida S Smyth, Nadia El-Fawal, et al.Plos One|December 14, 2012
The P2Y(12) antagonists, 2MeSAMP and cangrelor, inhibit platelet activation through P2Y(12)/G(i)-dependent mechanismBinggang Xiang, Guoying Zhang, Hongmei Ren, et al.The Journal of Clinical Endocrinology and Metabolism|March 1, 1994
Somatotroph hyperplasia without pituitary adenoma associated with a long standing growth hormone-releasing hormone-producing bronchial carcinoidS Ezzat, S L Asa, L Stefaneanu, et al.Clinical Endocrinology|October 27, 2001
Distinct clonal composition of primary and metastatic adrencorticotrophic hormone-producing pituitary carcinomaA Zahedi, G L Booth, H S Smyth, et al.Plos One|August 31, 2011
CD40 is essential in the upregulation of TRAF proteins and NF-kappaB-dependent proinflammatory gene expression after arterial injuryZifang Song, Rong Jin, Shiyong Yu, et al.The American Journal of Cardiology|July 15, 1996
Prognostic value of plasma fibrinogen concentration in patients with unstable angina and non-Q-wave myocardial infarction (TIMI IIIB Trial)R C Becker, C P Cannon, E G Bovill, et al.Journal of the American College of Cardiology|February 11, 1999
Fatal cardiac rupture among patients treated with thrombolytic agents and adjunctive thrombin antagonists: observations from the Thrombolysis and Thrombin Inhibition in Myocardial Infarction 9 StudyR C Becker, J S Hochman, C P Cannon, et al.Southern Medical Journal|July 4, 2013
Fibrinolytic therapy versus primary percutaneous coronary interventions for ST-segment elevation myocardial infarction in Kentucky: time to establish systems of care?Eric L Wallace, John R Kotter, Richard Charnigo, et al.Journal of Thrombosis and Thrombolysis|December 1, 2020
Cangrelor in addition to standard therapy reduces cardiac damage and inflammatory markers in patients with ST-segment elevation myocardial infarctionMohamed Abo-Aly, Bennet George, Elica Shokri, et al.Pageof 40